



## **Dhananjay Patankar, PhD**

Dr. Dhananjay Patankar, Ph.D. is Head of Pharmaceutical and Biopharmaceutical Development at Syngene International Ltd., a leading contract research, development and manufacturing organization. Dr. Patankar heads the biologics development and manufacturing business. Prior to joining Syngene, he was involved in the development and manufacturing of several biosimilars for the Indian and global markets. He also serves on US Pharmacopeia Expert Committee in Biologics, and is on the Executive Council of ABLE, the biotechnology industry body in India.

**Title of the Presentation:** Monoclonal antibodies: moving beyond the high profile

**Abstract:**

Monoclonal antibodies have become the dominant class of biologic drugs in the market today. Most of the antibodies have traditionally targeted cancer, rheumatoid arthritis and other therapy areas requiring high production volumes but also commanding high prices.

Recently, monoclonal antibody development is also extending beyond these traditional areas to newer applications including niche patient populations, veterinary medicine, and even mass market infectious diseases. These applications will also challenge the manufacturing technologies to provide cheaper and flexible solutions for the divergent demands of these segments. The talk will provide an overview of these recent trends covering new areas of application and new manufacturing technologies.